Several intracellular mediators have been implicated as new therapeutic targets against myocardial ischaemia and reperfusion injury. However, clinically effective salvage pathways remain undiscovered. Here, we focused on the potential role of the adaptor protein p66
Introduction
Myocardial injury during short-term ischaemia and reperfusion has become clinically important with the use of primary percutaneous coronary angioplasty as a first-line strategy in patients with acute coronary syndrome (ACS). Indeed, time from symptom onset to reperfusion is a major determinant of outcome. 1 Thus, activation of protective pathways during this vulnerable period of ACS remains a clinical need. Knowledge of the mechanisms of myocardial ischaemia and reperfusion has been deepened with the use of animal models of human disease. 2, 3 Several molecular and cellular targets involved in cardiac injury and repair have been identified that are activated to protect cardiomyocytes from ischaemic insults. 4 -7 Indeed, a large number of protein kinases are activated at different levels and time points during ischaemia-reperfusion injury. Recently, three distinct cardioprotective pathways for those protein kinases have been proposed. 8 The first is activated during the initial and middle phase of acute ischaemic preconditioning and includes activation of phosphoinositide 3 kinase (PI3K)/Akt and in turn endothelial nitric oxide synthase (eNOS) and nitric oxide, followed by guanylate cyclase and protein kinase C activation leading to activation of the ATPdependent mitochondrial potassium channels and generation of reactive oxygen species (ROS), 9, 10 finally activating mitogen-activated protein kinase p38 and mitochondrial permeability pore (mPTP) opening. 11 The second becomes active during the early in reperfusion and results in the activation of the Reperfusion Injury Salvage Kinases (RISK) pathway, which comprises PI3K and extracellular signalregulated mitogen-activated protein kinase (ERK1/2), and leads to the inhibition of mPTP opening. The third is recruited during ischaemic pre-and post-conditioning and includes the Survivor Activating Factor Enhancement (SAFE) pathway, which comprises signal transducer and activator of transcription (Stat) and results in rearrangements in the nucleus and mitochondria. 12 The complex interplay between these intracellular pathways remains largely unknown, but might represent a promising target to reduce cardiac damage during ischaemia and reperfusion. In this context, cardiac ROS released following ischaemia-reperfusion are of interest as regulators of cardiac salvage pathways. 13 To investigate this, we focused on the adaptor protein p66 Shc which regulates cellular redox states, metabolism and life span and is a critical mediator of oxidative signal transduction. 14 -17 p66 Shc acts not only in the cytosol but upon phosphorylation also as a specific redox enzyme in mitochondria, generating hydrogen peroxide. 18 As such, the adaptor protein p66 Shc might regulate ischaemia-reperfusion damage. 19, 20 However, whether such effects occur in vivo remains unknown.
Thus, we designed an in vivo study to investigate the role of this protein in a mouse model of ischaemia and reperfusion taking advantage of genetic deletion of p66 Shc 
Materials and methods

Animals
P66
Shc2/2 knockout mice were originally obtained from the Centro Nationale di Oncologia, Milano, Italy. 15 The p66 Shc deficient mouse colony was maintained in the own animal facility by crossbreeding homozygous animals. All animal experiments were performed on 12-to 14-week-old p66 Shc2/2 knockout and wild-type (WT) male mice. Both animal cohorts were maintained on identical C57Bl/6 genetic background. Genotyping was performed by PCR on ear punch biopsies using p66
Shc -specific primers (data not shown). All mice were maintained at 248C with 12 h light -dark cycle and free access to food and water. They were kept on a standard western type chow. All procedures were approved by local ethics committees (both in Zurich and Geneva) and Swiss authorities and conformed to the 'position of the American Heart Association on Research Animal Use' and ARRIVE guidelines.
In situ hybridization
P66
Shc In situ hybridization was performed using Leica BOND-MAX TM (Leica Biosystems, Buffalo Grove, IL, USA). Briefly, isolated murine WT and p66 Shc2/2 hearts were fixed in 4% paraformaldehyde in phosphatebuffered saline (PBS) for 24 h. Formalin-fixed paraffin-embedded tissue sections (5 mm) were deparaffinized in xylene, rehydrated in ascending alcohols, digested with Enzyme 2 (5 g/mL) for 15 min at ambient temperature. Samples (heart sections) were then denatured on a hot plate for 3 min at 908C, and incubated for 1 h at 538C in hybridization buffer (Exiqon, Woburn, MA, USA) containing 250 nM of double digoxigeninlabeled p66 Shc LNA mRNA detection probe (Exiqon). After incubation, the samples were washed twice in BOND washing buffer at ambient temperature for 5 min. The samples were incubated in blocking solution (AB-Blocking kit, Cell Marque, Rocklin, CA, USA), supplemented with 1 : 500 mouse anti-digoxigenin secondary Ab (Sigma) in BOND diluent buffer (Leica Biosystems) and detected with the BOND Polymer Refine Detection kit (Leica Biosystems).
In vivo knockdown of p66
Shc
In vivo knockdown of p66 Shc was performed by injecting a predesigned siRNA specifically targeting p66 Shc (5 ′ -UGA GUC UCU GUC AUC GCU G dTdT-3 ′ , Microsynth AG, Switzerland). A scrambled siRNA P66 deletion and myocardial infarction was used as a negative control (5 ′ -UAC ACA CUC UCG UCU CU dTdT-3 ′ , Microsynth AG, Switzerland). Amount of p66 Shc siRNA was selected based on dose optimization studies (data not shown).
The siRNA mix at the final dose of 1.6 mg/kg was incubated with the in vivo-jetPEI delivery reagent (Polyplus-Transfection, Inc., New York, NY, USA) for 15 min at room temperature and intravenously injected in a final volume of 160 mL, as previously reported. 21 Successful knockdown of p66 Shc was assessed by western blot in heart lysates.
In vivo pharmacological inhibition of Stat3
Some WT and p66 Shc2/2 knockout mice were pretreated with WP1066
(40 mg/kg, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or vehicle (10% DMSO in PBS) by intraperitoneal injection 5 min before ischaemia onset. Then, at 24 h of reperfusion, mice were euthanized and infarct size was histologically determined by triphenyltetrazolium chloride (TTC) staining.
Ischaemia and reperfusion in vivo
P66
Shc2/2 and WT (including those injected with siRNA) male mice (10 -12 weeks of age) were initially anaesthetized with 4% isoflurane and intubated. After starting mechanical ventilation (tidal volume of 150 mL, 120 breaths/min) by supplementation with 100% oxygen, anaesthesia was maintained with 2% isoflurane. During surgery anaesthesia was monitored by careful visual and tactile control of mouse consciousness (i.e. breathing rate and volume, heart rate, sweating and tearing). A thoracotomy was performed in the left third intercostal space and the pericardium was removed. Ligature of the left anterior coronary artery at the inferior edge of the left atrium was performed using an 8-0 Prolene suture. A small piece of polyethylene tube was used to secure the ligature without damaging the artery. After 30, 45, or 60 min of ischaemia, the occlusion of the left anterior coronary artery occlusion was released and reperfusion occurred. Analgesia was extended with s.c. injection of 0.05 mg/kg buprenorphine HCl every 12 h till sacrifice. Reperfusion was confirmed by visible restoration of colour to the ischaemic tissue. Then, chest was closed and the ventilator removed to restore normal respiration. After 24 h of reperfusion, animals were anaesthetized with 4% isoflurane and i.p. injection of ketamine-xylazine (4 mg/0.2%) and sacrificed for infarct size determination and immunohistochemical analyses.
Area at risk and myocardial infarct size (I ) assessment
To assess area at risk (AAR) and infarct size (I ) in in vivo myocardial protocols, mice were anaesthetized with ketamine -xylazine and sacrificed at 24 h of reperfusion, as described. 22 Left anterior coronary artery was re-occluded before the heart was taken out. Next, Evan's blue dye (2%; Sigma, St. Louis, MI, USA) was injected into the aortic cannula to delineate the in vivo AAR. The heart was rapidly excised and rinsed in NaCl 0.9%. Then, hearts were frozen and sectioned into 2-mm transverse sections from the apex to the base (5 -6 slices/heart). The sections were incubated at 378C with 1% TTC (Sigma) in phosphate buffer (pH 7.4) for 15 min, fixed in 10% formaldehyde solution and photographed with a digital camera (Nikon Coolpix) to distinguish continuously perfused tissue (blue), stained ischaemic viable tissue (red), and unstained necrotic tissue (white). The different zones were determined using MetaMorph software (version 6.0, Universal Imaging Corporation). Area at risk and left ventricular I were expressed as percentage of ventricle surface (AAR/V) and AAR (I/AAR), respectively.
Detection of cardiac troponin I and inflammatory mediators in mouse serum
Circulating cardiac troponin I (cTnI) levels were measured in serum after 24 h of reperfusion, using a high-sensitive ELISA kit (Life Diagnostics, Inc.). Serum levels of CXCL1 and CCL2 were measured by colorimetric enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN, USA), following manufacturer's instructions. The limit of detection was 0.156 ng/mL for cTnI, 15.6 pg/mL for CXCL1, 7.8 pg/mL for CCL2. Mean intra-and interassay coefficients of variation were ,6% for all mediators.
Immunostaining
Hearts from animals sacrificed both before and after 30 min of ischaemia and 24 h of reperfusion were frozen in optimal cutting temperature and serially cut from the occlusion locus to the apex in 7 mm sections. Immunostainings for neutrophils (anti-mouse Ly-6G Ab, dilution 1 : 100; BD Pharmingen TM , San Jose, CA, USA), macrophages (anti-mouse CD68 Ab, dilution: 1 : 400; ABD Serotec, Dusseldorf, Germany), endothelial (anti-mouse CD31 Ab, dilution 1 : 500, Santa Cruz Biotechnology) or smooth muscle cells (anti-mouse smooth muscle actin Ab, dilution 1 : 20, Thermo Scientific, Inc., Waltham, MA, USA) were performed on five midventricular cardiac or brain sections per animal, and quantification performed with the MetaMorph software, as previously described.
-24
Oxidative stress determination in mouse infarcted hearts
Measurement of O 2
− in mouse hearts at 30 min of ischaemia and 24 h of reperfusion was performed using the O 2 − -sensitive dye dihydroethidium (DHE, Molecular Probes, Life Technologies Corporation, Zug, Switzerland) as previously described. 22 Five frozen midventricular cardiac sections per animal were used, and nuclei were stained with 4 ′ ,6-diamidino-2-phenylindole. In situ fluorescence was assessed using fluorescence microscopy and quantification performed with MetaMorph software.
The production of other ROS was assessed by two histological mediators: the highly toxic product of lipid membrane peroxidation 4-hydroxy-2-nonenal (mouse anti-4-HNE monoclonal antibody at 1 mg/mL, Oxis International, Inc., Foster City, CA, USA) and the 3,5-dibromotyrosine (mouse anti-Di bromo tyrosine monoclonal antibody at 10 mg/mL, AMS biotechnology, LTD, Abingdon, UK). 22 To avoid any potential cross-reactivity with mouse heart antigens and to increase the specificity of the primary antibodies, the VECTOR M.O.M Immunodetection kit and the VECTOR VIP substrate kit for peroxidase (Vector Laboratories, Inc. Burlingame, CA, USA) were used, following the manufacturer's instructions. Quantification was performed with MetaMorph software. Results were expressed as percentages of stained area on total heart surface area.
Western blotting
Mouse hearts were isolated after 30 min of ischaemia followed by either 5 or 15 min of reperfusion and were homogenized in lysis buffer containing 50 mM Tris, pH 7.5, 1 mM EDTA, pH 8.0, 150 mM NaCl, 1 mM PMSF, and 1 mM DTT. Total protein extracts were cleared by centrifugation and 40 mg of proteins separated by gel electrophoresis on 10% SDS -polyacrylamide gel followed by semi-dry transfer onto PVDF membranes. Membranes were incubated with primary anti-phospho-Akt(Thr308), anti-phospho-Akt(Ser473), anti-Akt, anti-phospho-p42/p44 MAPK, anti-p42/p44 MAPK, anti-phospho-p38 MAPK, anti-p38 MAPK, antiphospho-Stat3(Ser727), anti-phospho-Stat3(Tyr705), anti-Stat3, antiphospho-SAPK/JNK(Thr183/Tyr185), and anti-SAPK/JNK antibody (all from Cell Signaling, Danvers, MA, USA). Primary anti-GAPDH (Millipore Corporation, Billerica, MA, USA) antibodies were used as loading control. Protein expression was quantified using Scion Image TM and expressed as ratio to corresponding loading control.
Mitochondrial swelling assay
Mitochondria (40 mg) from mouse hearts submitted to 30 min ischaemia and 24 h of reperfusion were isolated in swelling buffer (250 mM sucrose, 10 mM 3-(n-morpholino)propanesulfonic acid, 5 mM EGTA, 2 mM MgCl 2 , 5 mM KH 2 PO 4 , 5 mM pyruvate, and 5 mM malate) were incubated with 150 mM CaCl 2 in a final volume of 200 mL in 96-well plate for 20 min. Absorbance at 520 nm was read every 5 min. 25 
Caspase 3 assay
The caspase 3 assay was performed in total protein extracts from murine hearts after 30 min ischaemia and 5 -15 min of reperfusion, using caspase 3 colorimetric assay kit (Sigma), according to manufacturer's recommendations.
Apoptotic cell measurement within infarcted hearts
Apoptosis was evaluated on cryosections of infarcted hearts after 30 min of ischaemia and 24 h of reperfusion. The staining was performed using the Dead End TM colorimetric terminal deoxinucleotidyltransferasemediated dUTP nick end labelling (TUNEL) system (Promega, Madison, WI, USA). Diaminobenzidine was used as the chromogenic substrate (according to the manufacturer's instructions). Results were expressed as percentages of stained area on total heart surface area.
Statistical analysis
The Mann-Whitney nonparametric test (the normality assumption of the variables' distribution in both groups was violated) was used for comparisons of continuous variables. Kruskal -Wallis one-way analysis of variance was used for multiple group comparison. All results are expressed as mean + SEM. Values of P , 0.05 (two tailed) were considered significant. All analyses were done with GraphPad Prism software version 5.01.
Results
Expression pattern of p66 Shc in cardiac tissue
To determine the expression of p66
Shc within cardiac tissue, we performed in situ hybridization of paraffin-embedded cross sections of perfused hearts isolated from WT and p66 Shc2/2 mice using a p66 Shc -specific probe. In order to allocate p66 Shc staining to cardiomyocytes, we performed H/E staining of adjacent sections ( Figure 1 ).
To visualize heart vessels and arterioles, we used smooth muscle of reperfusion. The AAR after 30 min of ischaemia were comparable for both genotypes indicating that coronary ligatures were placed at the same level of the LAD in both groups (Figure 2A) Figure 2B ). In contrast, after prolonged ischaemia of 45 or 60 min, despite comparable areas at risk ( Figure 2C and E), infarct size was similar in both groups ( Figure 2D and F ). This indicates that p66 Shc2/2 mice display an increased susceptibility to ischaemia leading to larger infarcts at shorter, but not prolonged periods of ischaemia. Serum cTnI levels (a biomarker of cardiac necrosis) 22, 27 confirmed the histological results with significantly higher levels in p66 Shc2/2 mice only after 30 min of ischaemia ( Figure 2G-I) . Heart vessels (CD31+) or intramyocardial and coronary arterioles (SMA+) did not differ in p66
Shc2/2 mice after ischaemia and reperfusion compared with WT as assessed by smooth muscle actin and CD31 immunostaining, respectively (see Supplementary material online, Figure S3 ). Finally, we found that expression of p66 Shc protein in the heart from WT subjected to 30 min of ischaemia followed by either 12 or 24 h of reperfusion was increased compared with p66 Shc protein expression without cardiac injury (see Supplementary material online, Figure S4 ). Figure 3A) . We first confirmed that p66 Shc was significantly downregulated at the protein level upon in vivo siRNA treatment ( Figure 3B ) and that the AAR was similar in all treatment groups ( Figure 3C ). Similar to p66 Shc2/2 mice, p66 Shc -siRNA-mediated silencing was associated with a significant increase in infarct size as compared with controls at 30 min of ischaemia (14.9% + 2.4 vs. 9.4% + 2.9, Figure 3D and E). Again, there was no difference in arteriole or vessel density in WT mice injected 
Genetic deletion or in vivo knockdown of p66 Shc do not influence inflammatory processes during ischaemia and reperfusion
In order to investigate whether genetic deletion or silencing of p66
Shc influences post-infarction inflammation (a critical mechanism of injury during reperfusion) 22,28 after short-term myocardial ischaemia, we investigated systemic levels of CC and CXC chemokines (attracting inflammatory cells), 22 cardiac leukocyte infiltration as well as cardiac oxidant content. No differences between p66 Shc2/2 and WT were noted in serum CXCL1 or CCL2 levels at 30 (Table 1 ) min of ischaemia followed by 24 h of reperfusion. Although some trend towards an increase for CXCL1 was observed in WT mice submitted to in vivo siRNA-mediated knockdown of p66 Shc , serum levels of both CXCL1 and CCL2 remained unchanged in p66 Shc siRNA-treated animals when compared with scr siRNA controls after 30 min of ischaemia and 24 h of reperfusion ( Table 1) . As a consequence of these negligible differences between genotypes on post-infarction circulating levels of CC and CXC chemokines, p66 Shc2/2 mice and WT mice exhibited similar levels of infiltrating neutrophils (Ly-6G+ cells, Supplementary material online, Figure S6A ), macrophages (see Supplementary material online, Figure S6B Figure S7A ), macrophages (see Supplementary material online, Figure S7B ), or ROS (see Supplementary material online, Figure 7C -E) within infarcted hearts when compared with scr siRNA controls. Finally, no significant changes were observed in basal cardiac and brain ROS levels in both groups of mice as assessed by 4-HNE and DiBrY stainings (see Supplementary material online, Figures S8 and S9 ).
Genetic deletion of p66 Shc prevents activation of RISK and SAFE salvage pathways
Activation of survival protective pathways in response to shortterm ischaemia early during reperfusion was then investigated. 12, 29 We examined phosphorylation levels of Akt, ERK1/2 and Stat3, key members of RISK (Akt and ERK1/2) and SAFE (Stat3) intrinsic prosurvival signalling pathways known to limit reperfusion injury, during first 5 and 15 min of reperfusion. Significant abrogation in the phosphorylation of Akt (Thr308) and Stat3 (Ser727) was obvious at 5, but not at 15 min of reperfusion in p66 Shc2/2 mice when compared with WT, indicating a transient inhibition of these salvage pathways ( Figure 4A and C ). p66 Shc deficiency was not associated with any modification in the phosphorylation of other amino acid residues of Akt (Ser473) or Stat3 (Tyr705) neither at 5 nor at 15 min of reperfusion ( Figure 4B and D) . On the other hand, no significant change in ERK1/2 phosphorylation was noted in p66 Shc2/2 animals when compared with WT (Supplementary material online, Figure S10 ). Finally, both WT and p66 WP1066-treated groups when compared with corresponding vehicle controls ( Figure 4G ).
Genetic deletion and in vivo knockdown of p66 Shc promotes mitochondrial swelling and apoptosis in infarcted hearts
Phosphorylation of Stat3 on tyrosine 705 is known to drive p66 Shc to the nucleus, whereas the phosphorylation on serine 727 drives the adaptor protein to the mitochondria where it regulates permeability transition pores (PTP). 30 To investigate the impact of Stat3 (Ser727) phosphorylation on mitochondrial function, we performed swelling assay using isolated mitochondria from WT and p66 Shc2/2 infarcted hearts induced by calcium chloride overload (CaCl 2 ). The rate of mitochondrial swelling was measured by light scattering at 520 nm. Stable absorbance at 520 nm was observed up to 20 min in extracts from WT mice. In contrast, mitochondria of p66 Shc2/2 hearts displayed significantly increased absorbance 15 and 20 min after CaCl 2 overload reflecting markedly increased swelling and thus mitochondrial disruption ( Figure 5A) . Accordingly, caspase-3 activity was increased in heart extracts from p66 2/2 mice after 15 min of reperfusion when compared with WT ( Figure 5B Data are presented as mean + SD; n ¼ 10 -18 per group.
Figure 4 Genetic deletion of p66
Shc inhibits early activation of salvage signalling pathways in infarcted hearts. After 30 min ischaemia followed by 5 -15 min of reperfusion, hearts were lysed and phosphorylation of intracellular kinases assessed by western blot. n ¼ 7 for wild type and n ¼ 6 for P66 deletion and myocardial infarction increased Tunel-positive cell content when compared with WT ( Figure 5C ). A similar result was also seen in p66 Shc siRNA-treated mice when compared with scr siRNA controls ( Figure 5D ).
Discussion
This study for the first time demonstrates that, unlike in the brain,
p66
Shc protects the myocardium during short-term ischaemia and reperfusion from injury in vivo in mice. Indeed, we showed that (1) p66 Shc is expressed both in the myocardium and the coronary vasculature, (2) p66 Shc2/2 mice display increased infarct size when compared with WT controls when exposed to a short-term period of ischaemia only (i.e. 30 min), (3) similar effects can be obtained in WT mice by transient silencing of p66 Shc using siRNA,
p66 Shc regulates salvage pathways, and (4) prevents mitochondrial swelling and apoptosis via caspase-3. P66 Shc is differentially expressed in different organs and tissues.
Importantly, unlike in the brain (where p66 Shc is exclusively expressed in the endothelium of blood vessels), 19 in the heart the adaptor protein is expressed both in myocardial tissue and coronary blood vessels. At baseline, p66 Shc knockout mice did not differ from WT in their vessel structure and density or metabolism of reactive oxidant species in both the heart and brain. Similarly, in infarcted hearts after 30 min of ischaemia and 24 h of reperfusion, no histological alterations of vessel density and structure or oxidant content were notable. This demonstrates that p66 Shc plays distinct roles at baseline and in response to an ischaemic insult in the heart and brain. The surprising fact that both genetic deletion or transient silencing of p66
Shc led to increased infarct size after 30, but not after 45 and 60 min of ischaemia followed by 24 h reperfusion was supported by histological and biochemical data using troponin I as a marker. These solid observations are in contrast to previous ex vivo studies using isolated perfused hearts where p66 Shc deletion appeared to prevent from ischaemia-reperfusion injury. 20 Thus, as in other experimental situations, it is obvious that results obtained in isolated organs and tissues mostly perfused by artificial solutions and devoid of physiological filling pressure and neurohumoural regulation cannot be extrapolated to the in vivo situation. Indeed, ex vivo and in vivo models of ischaemic cardiac injury differ substantially (including different times of reperfusion and involvement of systemic inflammation). 31 -34 However, the microcirculation of the heart (which is of importance during ischaemia) is mainly regulated by endothelium-derived hyperpolarizing factors rather than eNOS. 17, 35, 36 Thus, the protective effects of p66 Shc against short-term ischaemia and reperfusion must be related to a specific role of the adaptor protein in the myocardium. Indeed, in the heart, ROS may also play a protective role in response to ischaemia. 22, 37 However, under our experimental conditions, p66 Shc silencing unlike in the murine aorta did not alter ROS production confirming a different regulatory role of p66 Shc in the heart compared with other organs. 38 Thus, the protective role of p66 Shc in the myocardium must involve other pathways than those described in endothelial cells of conduit arteries. Indeed, the fact that protein levels of p66 Shc in the infarcted hearts from WT mice increase after 30 min of ischaemia followed by 12 or 24 h of reperfusion support our initial hypothesis of a protective role of p66 Shc in the myocardium. Further, p66 Shc deficiency was not associated with any modification in both systemic and cardiac inflammation postinfarction. This again was surprising, since inflammation is considered a critical mediator of myocardial injury after ischaemia and reperfusion. 5, 6 However, our findings are in accordance with recent studies in animal models of acute myocardial infarction, in which the relevance of pro-inflammatory mediators (such as cytokines and chemokines) was questioned. 39 Furthermore, no anti-inflammatory interventions have been shown to be clinically effective. 40 -42 It even has been suggested that inhibition of certain chemokines may favour scar formation, salvage of post-infarction remodelling and mouse survival. 27 On the other hand, others found that inhibiting CXC chemokines early after ischaemia may reduce infarct size, but ineffective in preventing post-infarction heart failure. 43, 44 Be it as it may, p66 Shc does clearly not exert its protective effects via modulation of inflammatory responses or ROS activated during ischaemia and reperfusion. Shc is associated with increased apoptosis post-infarction in response to short-term ischaemia and reperfusion. In line with these morphological findings, caspase-3 activity was increased and marked mitochondrial swelling was noted in infarcted hearts obtained from p66 Shc2/2 when compared with WT animals. Of note, post-infarction cardiac apoptosis is a key event in adverse cardiac remodelling and heart failure during follow-up. 50 
Study limitations
First, extrapolations from mouse models to the human situation are difficult. Thus, although p66 Shc is upregulated in peripheral cells of patients with infarction further experiments in human myocardial tissue should be considered. Second, we acknowledge that infarct size observed in the present study was rather small compared with the infarct size found in humans, and accordingly small was the potential for protection. Third, the use of conventional knockout mice does not exclude effects of p66 Shc deletion in the other cell types than cardiomyocytes. Fourth, it is not clear yet whether further activation of p66 Shc over the basal level would be beneficial. To sort this out, the development of mice overexpressing p66 Shc in the myocardium would be essential. Fifth, although we were able to identify p66
Shc as a regulator of protective pro-survival RISK and SAFE pathways within ischaemic hearts, we did not identify all intermediate molecules involved. Finally, the present study also adds complexity to the use of this salvage pathways as a potential therapeutic target. Indeed, given the different effects of activation and silencing of P66 deletion and myocardial infarction p66 Shc in different cells, tissues, and organs, 17 tissue selective inhibition was shown to be effective in mice. Indeed, while shortterm activation might be protective in the context of an acute myocardial infarction, long-term inhibition may prevent endothelial dysfunction, 34, 38 atherosclerosis, and diabetic vascular disease in mouse models. 21, 34 Obviously, this complexity also raises safety and bio-efficacy concerns for translating these results to human domain. Additional research is needed to further clarify the role of p66 Shc in other animal models of acute myocardial infarction, before speculating on human diseases.
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